Neoantigens in Ovarian Cancer: Embarrassment of Riches or Needles in a Haystack?

Area of Science:

• Immunology
• Genomics
• Oncology

Background:

• Recurrent ovarian cancer presents significant treatment challenges.
• Understanding the tumor immune microenvironment is crucial for developing novel therapies.
• Neoantigens derived from tumor-specific mutations can potentially elicit anti-tumor immune responses.

Purpose of the Study:

• To identify and characterize tumor-infiltrating lymphocytes (T lymphocytes) that respond to mutated neoepitopes in recurrent ovarian cancer.
• To investigate the specificity of these T lymphocytes against common cancer-associated mutations.

Main Methods:

• Comprehensive genomic and transcriptomic analysis of tumor samples from patients with recurrent ovarian cancer.
• Identification and isolation of tumor-infiltrating T lymphocytes.
• Assessment of T-cell reactivity against identified neoepitopes, including TP53 mutations.

Main Results:

• Demonstrated the presence of T lymphocytes infiltrating recurrent ovarian tumors.
• Identified T-cell populations that react to mutated neoepitopes specific to the tumor.
• Found that two T-cell populations recognized hotspot missense mutations in the TP53 gene, which are prevalent across various malignancies.

Conclusions:

• Tumor-infiltrating T lymphocytes reactive to neoepitopes can be detected in recurrent ovarian cancer.
• TP53 mutations represent a potential target for T-cell-mediated immunotherapy in ovarian and other cancers.